Precipio (PRPO) 10-Q 13 Aug 24 2024 Q2 Quarterly report Financial data

DOCUMENT AND ENTITY INFORMATION

DOCUMENT AND ENTITY INFORMATION - shares	6 Months Ended
	Jun. 30, 2024	Aug. 09, 2024
Document and Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-36439
Entity Registrant Name	PRECIPIO, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	91-1789357
Entity Address, Address Line One	4 Science Park
Entity Address, City or Town	New Haven
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06511
City Area Code	203
Local Phone Number	787-7888
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	PRPO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,482,133
Entity Central Index Key	0001043961
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash	$ 1,279	$ 1,502
Accounts receivable (net of allowance for credit losses of $2,684 and $2,572, respectively)	1,107	1,301
Inventories	653	384
Other current assets	325	495
Total current assets	3,364	3,682
PROPERTY AND EQUIPMENT, NET	683	739
OTHER ASSETS:
Finance lease right-of-use assets, net	372	174
Operating lease right-of-use assets, net	498	612
Intangibles, net	12,343	12,818
Other assets	58	76
Total assets	17,318	18,101
CURRENT LIABILITIES:
Current maturities of long-term debt, less debt issuance costs	249	235
Current maturities of finance lease liabilities	105	132
Current maturities of operating lease liabilities	208	218
Accounts payable	855	622
Accrued expenses	2,918	1,824
Deferred revenue	260	110
Total current liabilities	4,595	3,141
LONG TERM LIABILITIES:
Long-term debt, less current maturities and debt issuance costs	92	106
Finance lease liabilities, less current maturities	215	18
Operating lease liabilities, less current maturities	301	407
Total liabilities	5,203	3,672
COMMITMENTS AND CONTINGENCIES (Note 5)
STOCKHOLDERS' EQUITY:
Preferred stock - $0.01 par value, 15,000,000 shares authorized at June 30, 2024 and December 31, 2023, 47 shares issued and outstanding at June 30, 2024 and December 31, 2023, liquidation preference of $30 at June 30, 2024
Common stock, $0.01 par value, 150,000,000 shares authorized at June 30, 2024 and December 31, 2023, 1,469,540 and 1,420,125 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	14	14
Additional paid-in capital	113,550	112,565
Accumulated deficit	(101,449)	(98,150)
Total stockholders' equity	12,115	14,429
Total liabilities and stockholders' equity	$ 17,318	$ 18,101

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]
Allowance for credit losses	$ 2,684	$ 2,572
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock, shares issued (in shares)	47	47
Preferred stock, shares outstanding (in shares)	47	47
Preferred stock, liquidation preference	$ 30
Common stock, par value (in $ per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	1,469,540	1,420,125
Common stock, shares outstanding (in shares)	1,469,540	1,420,125

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue, net of contractual allowances and adjustments	$ 4,507	$ 3,645	$ 7,985	$ 6,474
Adjustment for allowance for credit losses	(66)	(112)	(112)	(124)
Net sales	4,441	3,533	7,873	6,350
Total cost of sales	2,725	2,162	5,237	4,230
Gross profit	1,716	1,371	2,636	2,120
OPERATING EXPENSES:
Operating expenses	2,925	3,663	5,919	7,438
OPERATING LOSS	(1,209)	(2,292)	(3,283)	(5,318)
OTHER (EXPENSE) INCOME:
Interest expense, net	(11)	(1)	(16)	(5)
LOSS BEFORE INCOME TAXES	(1,220)	(2,293)	(3,299)	(5,323)
NET LOSS	$ (1,220)	$ (2,293)	$ (3,299)	$ (5,323)
LOSS PER COMMON SHARE, BASIC	$ (0.83)	$ (1.88)	$ (2.28)	$ (4.50)
LOSS PER COMMON SHARE, DILUTED	$ (0.83)	$ (1.88)	$ (2.28)	$ (4.50)
WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING, BASIC	1,463,543	1,218,139	1,444,742	1,189,525
WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING, DILUTED	1,463,543	1,218,139	1,444,742	1,189,525
Service revenue, net
Revenue, net of contractual allowances and adjustments	$ 3,909	$ 2,768	$ 6,730	$ 4,836
Adjustment for allowance for credit losses	(66)	(112)	(112)	(124)
Net sales	3,843	2,656	6,618	4,712
Total cost of sales	2,425	1,880	4,526	3,649
Product revenue
Revenue, net of contractual allowances and adjustments	598	877	1,255	1,638
Net sales	598	877	1,255	1,638
Total cost of sales	$ 300	$ 282	$ 711	$ 581

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total Precipio, Inc.	Noncontrolling Interest in Joint Venture	Total
Balance at beginning of period at Dec. 31, 2022		$ 11	$ 108,588	$ (92,297)	$ 16,302	$ 65	$ 16,367
Balance at beginning of period (in shares) at Dec. 31, 2022	47	1,141,013
Increase (Decrease) in Stockholders' Equity
Net loss				(5,323)	(5,323)		(5,323)
Issuance of common stock in connection with purchase agreements, net of issuance costs		$ 3	1,757		1,760		1,760
Issuance of common stock in connection with purchase agreements, net of issuance costs (in shares)		206,250
Issuance of common stock in connection with at the market offering, net of issuance costs			485		485		485
Issuance of common stock in connection with at the market offering, net of issuance costs (in shares)		30,852
Non-cash stock-based compensation			802		802		802
Balance at end of period at Jun. 30, 2023		$ 14	111,632	(97,620)	14,026	65	14,091
Balance at end of period (in shares) at Jun. 30, 2023	47	1,378,115
Balance at beginning of period at Mar. 31, 2023		$ 11	109,476	(95,327)	14,160	65	14,225
Balance at beginning of period (in shares) at Mar. 31, 2023	47	1,168,204
Increase (Decrease) in Stockholders' Equity
Net loss				(2,293)	(2,293)		(2,293)
Issuance of common stock in connection with purchase agreements, net of issuance costs		$ 3	1,757		1,760		1,760
Issuance of common stock in connection with purchase agreements, net of issuance costs (in shares)		206,250
Issuance of common stock in connection with at the market offering, net of issuance costs			47		47		47
Issuance of common stock in connection with at the market offering, net of issuance costs (in shares)		3,661
Non-cash stock-based compensation			352		352		352
Balance at end of period at Jun. 30, 2023		$ 14	111,632	(97,620)	$ 14,026	$ 65	14,091
Balance at end of period (in shares) at Jun. 30, 2023	47	1,378,115
Balance at beginning of period at Dec. 31, 2023		$ 14	112,565	(98,150)			14,429
Balance at beginning of period (in shares) at Dec. 31, 2023	47	1,420,125
Increase (Decrease) in Stockholders' Equity
Net loss				(3,299)			(3,299)
Issuance of common stock in connection with at the market offering, net of issuance costs			78				78
Issuance of common stock in connection with at the market offering, net of issuance costs (in shares)		11,822
Issuance of common stock for consulting services			251				251
Issuance of common stock for consulting services (in shares)		37,593
Non-cash stock-based compensation			656				656
Balance at end of period at Jun. 30, 2024		$ 14	113,550	(101,449)			12,115
Balance at end of period (in shares) at Jun. 30, 2024	47	1,469,540
Balance at beginning of period at Mar. 31, 2024		$ 14	112,989	(100,229)			12,774
Balance at beginning of period (in shares) at Mar. 31, 2024	47	1,430,292
Increase (Decrease) in Stockholders' Equity
Net loss				(1,220)			(1,220)
Issuance of common stock in connection with at the market offering, net of issuance costs			11				11
Issuance of common stock in connection with at the market offering, net of issuance costs (in shares)		1,655
Issuance of common stock for consulting services			251				251
Issuance of common stock for consulting services (in shares)		37,593
Non-cash stock-based compensation			299				299
Balance at end of period at Jun. 30, 2024		$ 14	$ 113,550	$ (101,449)			$ 12,115
Balance at end of period (in shares) at Jun. 30, 2024	47	1,469,540

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)	Sep. 21, 2023
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Abstract]
Reverse stock split	0.05

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,299)	$ (5,323)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation and amortization	601	621
Amortization of operating lease right-of-use asset	114	99
Amortization of finance lease right-of-use asset	35	43
Amortization of deferred financing costs, debt discounts and debt premiums	1	1
Stock-based compensation	656	802
Value of stock issued in payment of services	251
Provision for credit losses	112	124
Changes in operating assets and liabilities:
Accounts receivable	82	28
Inventories	(269)	171
Other assets	188	192
Accounts payable	233	353
Operating lease liabilities	(116)	(97)
Deferred revenue	150	(102)
Accrued expenses	1,094	311
Net cash used in operating activities	(167)	(2,777)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(70)	(54)
Net cash used in investing activities	(70)	(54)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on finance lease obligations	(35)	(44)
Deposits on finance lease right-of-use assets	(28)
Issuance of common stock, net of issuance costs	78	2,245
Proceeds from debt	250
Principal payments on long-term debt	(251)	(242)
Net cash flows provided by financing activities	14	1,959
NET CHANGE IN CASH	(223)	(872)
CASH AT BEGINNING OF PERIOD	1,502	3,445
CASH AT END OF PERIOD	1,279	2,573
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid during the period for interest	24	18
SUPPLEMENTAL DISCLOSURE OF CONSULTING SERVICES OR ANY OTHER NON-CASH COMMON STOCK RELATED ACTIVITY
Purchases of equipment financed through accounts payable		7
Operating lease right-of-use assets obtained in exchange for operating lease obligations	0	58
Finance lease right-of-use assets obtained in exchange for finance lease obligations	$ 205	$ 0

BUSINESS DESCRIPTION

BUSINESS DESCRIPTION	6 Months Ended
	Jun. 30, 2024
BUSINESS DESCRIPTION [Abstract]
BUSINESS DESCRIPTION	1. BUSINESS DESCRIPTION Business Description. Precipio, Inc., and its subsidiaries, (collectively, “we”, “us”, “our”, the “Company” or “Precipio”) is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. ​ Our products and services aim to deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. We develop innovative technologies in our laboratory where we design, test, validate, and use these products clinically. We believe these technologies improve diagnostic outcomes across various diseases within the hematologic field. We then commercialize these technologies as proprietary products that serve the global laboratory community in furtherance of our mission to eliminate or greatly reduce the prevalence of misdiagnosis. To deliver our strategy, we have structured our organization to develop diagnostic products, including our laboratory and research and development (“R&D”) facilities located in New Haven, Connecticut and Omaha, Nebraska, respectively, which house teams that collaborate on the development of new products and services. We operate clinical laboratory improvement amendment (“CLIA”) laboratories in both New Haven, Connecticut and Omaha, Nebraska where we provide essential blood cancer diagnostics to office-based oncologists in many states nationwide. To deliver on our strategy of mitigating misdiagnoses we rely heavily on our CLIA laboratory to support R&D beta-testing of the products we develop, in a clinical environment. ​ The development of laboratory products involves a qualified facility; highly skilled laboratory staff; and access to viable patient specimens to conduct development and testing. Our CLIA laboratory in New Haven, which is operated by our pathology services division, encapsulates these components, and also generates revenue for us which covers costs associated with operating this laboratory. This structure of utilizing our clinical lab to obtain samples and utilize the equipment and staffing to develop, test and validate our products, significantly reduces the development costs and timeline for our products. This also enables us to accelerate the time to market of new product development and launch. ​ Furthermore, as a clinical laboratory, we are always the first user of every product we develop, which allows us to optimize important laboratory functions such as workflow, inventory management, regulatory and billing issues. As a vendor, this places us as a reputable user of our own products, and we believe gains us significant credibility with existing and prospective customers. Furthermore, because we use our products as part of our day-to-day operations, we are able to deliver a high level of hands-on, experienced support to customers, improving their experience with our products. ​ Our Products Division commercial team generates direct sales and works with our key distributors. Global healthcare distributors, such as ThermoFisher, McKesson, and Cardinal Health, have partnered with us to form the backbone of our go-to-market strategy and enable us to access laboratories around the country that can benefit from using our diagnostic products. Our operating structure promotes the harnessing of our proprietary technology and genetic diagnostic expertise to bring to market our robust pipeline of innovative solutions designed to address the root causes of misdiagnoses. Going Concern. The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America (“GAAP”) applicable for a going concern, which assume that the Company will realize its assets and discharge its liabilities in the ordinary course of business and do not include any adjustments that might result should the Company be unable to continue as a going concern. The Company has incurred substantial operating losses and has used cash in its operating activities for the past several years. For the six months ended June 30, 2024, the Company had a net loss of $3.3 million and net cash used in operating activities of $0.2 million. As of June 30, 2024, the Company had an accumulated deficit of $101.4 million and a working capital deficit of $1.2 million. The Company’s ability to continue as a going concern over the next twelve months from the date of issuance of these condensed consolidated financial statements in this Quarterly Report on Form 10-Q is dependent upon a combination of achieving its business plan, including generating additional revenue and avoiding potential business disruption due to the macroeconomic environment and geopolitical instability, and raising additional financing to meet its debt obligations and paying liabilities arising from normal business operations when they come due. To meet its current and future obligations the Company has taken the following steps to capitalize the business: ● On April 14, 2023, the Company entered into a sales agreement with AGP, pursuant to which the Company may offer and sell its common stock having aggregate sales proceeds of up to $5.8 million, to or through AGP, as sales agent (the “AGP 2023 Sales Agreement”). The sale of our shares of common stock to or through AGP, pursuant to the AGP 2023 Sales Agreement, will be made pursuant to the registration statement (the “2023 Registration Statement”) on Form S-3 (File No. 333-271277), filed by the Company with the U.S. Securities and Exchange Commission (“SEC“) on April 14, 2023, as amended by Amendment No. 1 filed by the Company with the SEC on April 25, 2023, and declared effective on April 27, 2023. On April 8, 2024, we filed a prospectus supplement to our prospectus dated April 25, 2023 registering the offer and sale of up to $1,061,478 of shares of our common stock (the “April 2024 Prospectus Supplement”). As of the date the condensed consolidated financial statements were issued, the Company has approximately $3.7 million available for future sales pursuant to the 2023 Registration Statement, which includes approximately $1.0 million of remaining availability pursuant to the April 2024 Prospectus Supplement. See Note 7 Stockholders’ Equity, AGP 2023 Sales Agreement, for further discussion. ​ Notwithstanding the aforementioned circumstances, there remains substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the date these condensed consolidated financial statements were issued. There can be no assurance that the Company will be able to successfully achieve its initiatives summarized above in order to continue as a going concern over the next twelve months from the date of issuance of this Quarterly Report Form 10-Q.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2024
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation. The accompanying condensed consolidated financial statements are presented in conformity with GAAP. As required under GAAP, pursuant to a 1-for- 20 , unless otherwise indicated, the Company has adjusted all share amounts, per share data, share prices, exercise prices and conversion rates set forth in these notes and the accompanying condensed consolidated financial statements. Recently Adopted Accounting Pronouncements. In June 2022, the Financial Accounting Standards Board (the “FASB”) issued ASU 2022-03, Fair Value Measurement (Topic 820) (“ASU 2022-03”). The amendments in ASU 2022-03 clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments in this Update also require additional disclosures for equity securities subject to contractual sale restrictions. The Company adopted this guidance on January 1, 2024. The adoption of this standard was not material to our condensed consolidated financial statements. In August 2020, the FASB issued ASU 2020-06 “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity The adoption of this standard was not material to our condensed consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis, primarily through enhanced disclosures of significant segment expenses. The guidance will be effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 and requires retrospective application to all periods presented upon adoption, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its condensed consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09—Income Taxes (Topic 740)—Improvements to Income Tax Disclosures (“ASU 2023-09”) which is intended to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires additional disaggregation of the reconciliation between the statutory and effective tax rate for an entity and of income taxes paid, both of which are disclosures required by current GAAP. The amendments improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. The amendments in ASU 2023-09 apply to all entities that are subject to Topic 740, Income Taxes. For public business entities, the amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. ASU 2023-09 is effective for the Company beginning January 1, 2025. Adoption of ASU 2023-09 is expected to enhance the usefulness of income tax disclosures and is not expected to have a material impact on the Company’s financial position, results of operations or cash flow. Loss Per Share. Basic loss per share is calculated based on the weighted-average number of common shares (including pre-funded warrants) outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Shares of the Company’s common stock underlying pre-funded warrants are included in the calculation of basic and diluted loss per share due to the negligible exercise price of the pre-funded warrants. Options, warrants and conversion rights pertaining to 754,344 and 709,159 shares of our common stock have been excluded from the computation of diluted loss per share at June 30, 2024 and 2023, respectively, because the effect is anti-dilutive due to the net loss. The following table summarizes the outstanding securities not included in the computation of diluted net loss per share: ​ ​ ​ ​ ​ ​ ​ June 30, ​ 2024 2023 Stock options 304,025 231,802 Warrants 444,444 471,482 Preferred stock 5,875 5,875 Total 754,344 709,159 ​

LONG-TERM DEBT

LONG-TERM DEBT	6 Months Ended
	Jun. 30, 2024
LONG-TERM DEBT [Abstract]
LONG-TERM DEBT	3. LONG-TERM DEBT Long-term debt consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ Dollars in Thousands ​ June 30, 2024 December 31, 2023 Connecticut Department of Economic and Community Development (DECD) ​ $ 131 ​ $ 146 DECD debt issuance costs ​ (11) ​ (12) Financed insurance loan ​ — ​ 207 Business loan agreement ​ ​ 221 ​ ​ — Total long-term debt ​ 341 ​ 341 Current portion of long-term debt ​ (249) ​ (235) Long-term debt, net of current maturities ​ $ 92 ​ $ 106 ​ Department of Economic and Community Development. On January 8, 2018, the Company entered into an agreement with the Connecticut Department of Economic and Community Development (“DECD”) by which the Company received a loan of $300,000 secured by substantially all of the Company’s assets (the “DECD 2018 Loan”). The DECD 2018 Loan is a ten-year loan due on December 31, 2027 and includes interest paid monthly at 3.25%. The maturity date of the DECD 2018 Loan was extended to May 31, 2028 and the modification did not have a material impact on the Company’s cash flows. Amortization of the debt issuance costs were less than $1 thousand for the three months ended June 30, 2024 and 2023, respectively and $1 thousand for the six months ended June 30, 2024 and 2023, respectively. Financed Insurance Loan. The Company finances certain of its insurance premiums (the “Financed Insurance Loans”). In July 2023, the Company financed $0.4 million with a 9.99% interest rate and made payments on a monthly basis through June 2024. As of June 30, 2024 and December 31, 2023, the Financed Insurance Loan’s outstanding balance of zero and $0.2 million, respectively, was included in current maturities of long-term debt in the Company’s condensed consolidated balance sheets. A corresponding prepaid asset was included in other current assets. Business Loan Agreement. On May 1, 2024, the Company entered into a Business Loan and Security Agreement (the “Loan Agreement”) with Altbanq Lending LLC, pursuant to which the Company obtained a loan in the principal amount of $250,000 (the “Secured Loan”). According to the Loan Agreement, the Company granted the lender a continuing security interest in certain collateral (as defined in the Loan Agreement). Furthermore, the Company’s Chief Executive Officer provided a personal guaranty for the Secured Loan. The Secured Loan has a term of one year and an interest rate of 20%, such that pursuant to the Loan Agreement, the Company is obligated to pay the Lender 52 payments of $5,769 on a weekly basis and the total sum of the Secured Loan and interest (not including any fees) shall equal a total repayment amount of $300,000. If the Company defaults on payments then a default fee of $15,000 shall be payable to the lender. The Company has the right, at its discretion, to request the lender to loan an additional amount of up to $250,000 on the same terms and conditions as set forth in the Loan Agreement, provided that there has been no material change in the Company’s finances. ​ As of June 30, 2024 and December 31, 2023, the outstanding balance of $0.2 million and zero, respectively, under the Loan Agreement, was included in current maturities of long-term debt in the Company’s condensed consolidated balance sheets. ​

ACCRUED EXPENSES

ACCRUED EXPENSES	6 Months Ended
	Jun. 30, 2024
ACCRUED EXPENSES [Abstract]
ACCRUED EXPENSES	4 Accrued expenses at June 30, 2024 and December 31, 2023 are as follows: ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) June 30, 2024 December 31, 2023 Accrued expenses ​ $ 668 ​ $ 764 Accrued compensation ​ 993 ​ 754 Accrued franchise, property and sales and use taxes ​ ​ 181 ​ ​ 287 CHC temporary funding assistance ​ ​ 1,057 ​ ​ — Accrued interest ​ 19 ​ 19 ​ ​ $ 2,918 ​ $ 1,824 ​ The Company uses Change Healthcare (“CHC”), a healthcare technology company owned by UnitedHealth Group, to process some of its patient claims billings. In February 2024, CHC announced that it had experienced a cyberattack and as a result had to temporarily shut down some of its information technology systems. This system shut down caused delays in billing and reimbursement processes to CHC’s customers and, as a result, CHC established a Temporary Funding Assistance Program to help bridge the gap in short-term cash flow needs for customers affected by the disruption of its services due to the cyberattack. Funding distributed through this program is interest free and has no other fees or costs associated with it. As of June 30, 2024, CHC’s systems have yet to be fully restored. After CHC’s systems resume 100% of standard operations, any funds provided through the program will have to be repaid to CHC at a future date to be mutually agreed to by CHC and the Company. During the six months ended June 30, 2024, the Company received approximately $1.1 million through CHC’s Temporary Assistance Program.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2024
COMMITMENTS AND CONTINGENCIES [Abstract]
COMMITMENTS AND CONTINGENCIES	5 The Company is involved in legal proceedings related to matters, which are incidental to its business. Also, the Company is delinquent on the payment of outstanding accounts payable for certain vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts. See below for a discussion on these matters. PURCHASE COMMITMENTS The Company has entered into purchase commitments for reagents from suppliers. These agreements started in 2011 and run through 2025. The Company and the suppliers will true up the amounts on an annual basis. The future minimum purchase commitments under these and other purchase agreements are approximately $0.9 million at June 30, 2024. LITIGATIONS CPA Global provides us with certain patent management services. On February 6, 2017, CPA Global claimed that we owed approximately $0.2 million for certain patent maintenance services rendered. CPA Global has not filed claims against us in connection with this allegation. A liability of less than $0.1 million has been recorded and is reflected in accounts payable within the accompanying condensed consolidated balance sheets at June 30, 2024 and December 31, 2023. LEGAL AND REGULATORY ENVIRONMENT The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, government healthcare program participation requirement, reimbursement for patient services and Medicare and Medicaid fraud and abuse. Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Management believes that the Company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations. While no material regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time.

LEASES

LEASES	6 Months Ended
	Jun. 30, 2024
LEASES [Abstract]
LEASES	6 The Company leases administrative facilities and laboratory equipment through operating lease agreements. In addition, we rent various equipment used in our diagnostic lab and in our administrative offices through finance lease arrangements. Our operating leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common area or other maintenance costs). The facility leases include one or more options to renew, from 1 to 5 years or more. The exercise of lease renewal options is typically at our sole discretion, therefore, the renewals to extend the lease terms are not included in our right-of-use (“ROU”) assets and lease liabilities as they are not reasonably certain of exercise. We regularly evaluate the renewal options and, when they are reasonably certain of exercise, we include the renewal period in our lease term. As our leases do not provide an implicit rate, we use our collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments. Operating leases result in the recognition of ROU assets and lease liabilities on the balance sheet. ROU assets represent our right to use the leased asset for the lease term and lease liabilities represent our obligation to make lease payments. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Lease expense is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The primary leases we enter into with initial terms of 12 months or less are for equipment. The Company also recognizes ROU assets from finance leases in connection with its HemeScreen Reagent Rental (“HSRR”) program. For certain customers in the HSRR program, the Company leases diagnostic testing equipment and then subleases the equipment to the customer. Finance lease ROU assets and finance lease liabilities are recognized at the lease commencement date, and at the sublease commencement date the finance lease ROU asset is derecognized and is recorded as cost of sales in the condensed consolidated statements of operations. There were no derecognized finance lease ROU assets for the three and six months ended June 30, 2024 and 2023, respectively. Where Precipio is the lessor, customers lease diagnostic testing equipment from the Company with the transfer of ownership to the customer at the end of the lease term at no additional cost. For these contracts, the Company accounts for the arrangements as sales-type leases. The lease asset for sales-type leases is the net investment in leased asset, which is recorded once the finance lease ROU asset is derecognized and a related gain or loss is noted. The net investment in leased assets was $0.1 million as of June 30, 2024 and December 31, 2023, respectively, and is included in other current assets and other assets in our condensed consolidated balance sheets. The balance sheet presentation of our operating and finance leases is as follows: ​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) ​ ​ ​ ​ ​ ​ Classification on the Condensed Consolidated Balance Sheet ​ June 30, 2024 ​ December 31, 2023 Assets: ​ ​ ​ ​ ​ ​ Operating lease right-of-use assets, net ​ $ 498 ​ $ 612 Finance lease right-of-use assets, net (1) ​ ​ 372 ​ ​ 174 Total lease assets ​ $ 870 ​ $ 786 ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ ​ ​ Current: ​ ​ ​ ​ ​ ​ Current maturities of operating lease liabilities ​ $ 208 ​ $ 218 Current maturities of finance lease liabilities ​ ​ 105 ​ ​ 132 Noncurrent: ​ ​ ​ ​ ​ ​ Operating lease liabilities, less current maturities ​ ​ 301 ​ ​ 407 Finance lease liabilities, less current maturities ​ ​ 215 ​ ​ 18 Total lease liabilities ​ $ 829 ​ $ 775 (1) As of June 30, 2024 and December 31, 2023, finance lease right-of-use assets included zero , respectively, of assets related to finance leases associated with the HSRR program. ​ As of June 30, 2024, the estimated future minimum lease payments, excluding non-lease components, are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) Operating Leases ​ Finance Leases ​ Total ​ ​ ​ June 30, ​ ​ June 30, ​ ​ June 30, ​ ​ ​ 2024 ​ ​ 2024 ​ ​ 2024 2024 (remaining) ​ $ 120 ​ $ 74 ​ $ 194 2025 ​ 224 ​ 134 ​ 358 2026 ​ 214 ​ 95 ​ 309 2027 ​ — ​ ​ 69 ​ 69 2028 ​ ​ — ​ ​ 29 ​ ​ 29 Total lease obligations ​ 558 ​ 401 ​ 959 Less: Amount representing interest ​ (49) ​ (81) ​ (130) Present value of net minimum lease obligations ​ 509 ​ 320 ​ 829 Less, current portion ​ (208) ​ (105) ​ (313) Long term portion ​ $ 301 ​ $ 215 ​ $ 516 ​ Other information as of June 30, 2024 and December 31, 2023 is as follows: ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2024 ​ 2023 Weighted-average remaining lease term (years): ​ ​ ​ Operating leases 2.4 ​ 2.8 Finance leases 3.0 ​ 2.0 Weighted-average discount rate: ​ ​ ​ Operating leases 8.00% ​ 8.00% Finance leases 13.62% ​ 10.63% ​ During the six months ended June 30, 2024 and 2023, operating cash flows from operating leases was $0.1 million, respectively, and operating lease ROU assets obtained in exchange for operating lease liabilities was zero, respectively. During the six months ended June 30, 2024 and 2023, finance lease ROU assets obtained in exchange for finance lease liabilities was $0.2 million and zero, respectively. Operating Lease Costs Operating lease costs were approximately $0.1 million during the three months ended June 30, 2024 and 2023, respectively, and $0.1 million and $0.2 million for the six months ended June 30, 2024 and 2023, respectively. These costs are primarily related to long-term operating leases for the Company’s facilities and laboratory equipment. Short-term and variable lease costs were less than $0.1 million for the three and six months ended June 30, 2024 and 2023, respectively. Finance Lease Costs Finance lease amortization and interest expenses are included in the condensed consolidated statements of operations for the three and six months ended June 30, 2024 and 2023. The balances within these accounts are less than $0.1 million, respectively.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended
	Jun. 30, 2024
STOCKHOLDERS' EQUITY [Abstract]
STOCKHOLDERS' EQUITY	7 Common Stock. Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have 150,000,000 shares of common stock authorized for issuance. On December 20, 2018, the Company’s shareholders approved the proposal to authorize the Company’s Board of Directors to, in its discretion, amend the Company’s Third Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock from 150,000,000 shares to 250,000,000 shares. The Company has not yet implemented this increase. During the three and six months ended June 30, 2024, the Company issued 37,593 shares of its common stock in connection with consulting services of approximately $0.3 million. At The Market Offering Agreement ​ AGP Sales Agreement ​ On April 2, 2021, the Company entered into a sales agreement with A.G.P./Alliance Global Partners (“AGP”), pursuant to which the Company was permitted to offer and sell its common stock, par value $0.01 per share (the “Common Stock”) (the “Shares”), having aggregate sales proceeds of up to $22.0 million. Shares can be sold either directly to or through AGP as a sales agent (the “AGP Sales Agreement”), from time to time, in an “at the market offering” (as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended) of the Shares (the “2021 ATM Offering”). The Company is limited in the number of shares it can sell in the 2021 ATM Offering due to the offering limitations currently applicable to the Company under General Instruction I.B.6. of Form S-3 and the Company’s public float as of the applicable date of such sales, as well as the number of authorized and unissued shares available for issuance, in accordance with the terms of the AGP Sales Agreement. ​ The sale of our shares of Common Stock to or through AGP, will be made pursuant to the registration statement (the “Registration Statement”) on Form S-3 (File No. 333-237445), which was declared effective by the SEC on April 13, 2020, for an aggregate offering price of up to $50.0 million. Under the AGP Sales Agreement, Shares were permitted to be sold by any method permitted by law deemed to be an “at the market offering.” AGP will also be able to sell shares of Common Stock by any other method permitted by law, including in negotiated transactions with the Company’s prior written consent. Upon delivery of a placement notice and subject to the terms and conditions of the AGP Sales Agreement, AGP was required to use its commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations, and the rules of The Nasdaq Capital Market to sell the Shares from time to time based upon the Company’s instructions, including any price, time or size limits specified by the Company. AGP is not under any obligation to purchase any of the Shares on a principal basis pursuant to the AGP Sales Agreement, except as otherwise agreed by AGP and the Company in writing and expressly set forth in a placement notice. AGP’s obligations to sell the Shares under the AGP Sales Agreement are subject to satisfaction of certain conditions, including customary closing conditions. The Company is not obligated to make any sales of Shares under the AGP Sales Agreement and any determination by the Company to do so will be dependent, among other things, on market conditions and the Company’s capital raising needs. The Company agreed to pay AGP a cash fee of 3.0% of the aggregate gross proceeds from the sale of the Shares on the Company’s behalf pursuant to the AGP Sales Agreement. The AGP Sales Agreement contains representations, warranties and covenants that are customary for transactions of this type. In addition, the Company has provided AGP with customary indemnification and contribution rights. The Company also agreed to reimburse AGP for certain specified expenses, including the expenses of counsel to AGP. ​ During the three and six months ended June 30, 2023, we received net proceeds of $0.1 million and $0.5 million from the sale of 3,636 and 30,827 ​ As of the date of issuance of this Quarterly Report on Form 10-Q, we have received an aggregate of $15.6 million in net proceeds, after issuance costs of approximately $0.5 million, from the sale of 260,128 shares of common stock pursuant to the AGP Sales Agreement. The offering of the Shares pursuant to the AGP Sales Agreement terminated upon the expiration of the Company’s Registration Statement on Form S-3 (File No. 333-237445). ​ AGP 2023 Sales Agreement ​ On April 14, 2023, the Company entered into the AGP 2023 Sales Agreement, in an “at the market offering” (as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended) of the shares of Common Stock. AGP will be entitled to a commission at a fixed rate of 3.0% of the gross proceeds from each sale of shares of Common Stock pursuant to the AGP 2023 Sales Agreement. ​ The sale of our shares of Common Stock to or through AGP, pursuant to the AGP 2023 Sales Agreement, will be made pursuant to the 2023 Registration Statement on Form S-3 (File No. 333-271277), filed by the Company with the SEC on April 14, 2023, as amended by Amendment No. 1 filed by the Company with the SEC on April 25, 2023, and declared effective on April 27, 2023, for an aggregate offering price of up to $5.8 million. ​ On April 8, 2024, we filed a prospectus supplement (the “April 2024 Prospectus Supplement”) to our prospectus dated April 25, 2023 registering the offer and sale of up to $1,061,478 of shares of our common stock ​ During the three and six months ended June 30, 2023, we received net proceeds of less than $1 thousand, respectively, from the sale of 25 shares of common stock pursuant to the AGP 2023 Sales Agreement. ​ We have approximately $1.0 million of remaining availability pursuant to the 2024 Prospectus Supplement. ​ Registered Direct Offering ​ On June 8, 2023, the Company, entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, in a registered direct offering (the “Registered Direct Offering”), an aggregate of: (i) 206,250 shares (the “Shares”) of its common stock, $0.01 par value (the “Common Stock”), at a price of $9.00 per share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 15,972 shares of Common Stock, at a price of $8.98 per Pre-Funded Warrant. The Company reviewed the provisions of the Pre-Funded Warrants to determine the balance sheet classification and concluded that these warrants are to be classified as equity and are not subject to remeasurement on each balance sheet date. The Pre-Funded Warrants are immediately exercisable, have an exercise price of $0.02 per share, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. All of the Pre-Funded Warrants were exercised during the year ended December 31, 2023 and no Pre-Funded Warrants were outstanding as of June 30, 2024. In a concurrent private placement (the “Private Placement” and together with the Registered Direct Offering, the “Offering”), pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Purchasers, for no additional consideration, warrants (the “RDO Common Warrants” and, together with the Shares and the Pre-Funded Warrants, the “Securities”) to purchase up to 444,444 shares of Common Stock. The Company reviewed the provisions of the RDO Common Warrants to determine the balance sheet classification and concluded that these warrants are to be classified as equity and are not subject to remeasurement on each balance sheet date. The RDO Common Warrants are exercisable beginning six months after the date of issuance, have an exercise price of $12.60 per share, and will expire December 12, 2028. The fair value of the RDO Common Warrants of approximately $3.5 million at the date of issuance was estimated using the Black-Scholes model which used the following inputs: term of 5 years; risk free rate of 3.89%; volatility of 143%; and share price of $9.00 per share based on the trading price of the Company’s common stock. The Company allocated $1.3 million of the issuance proceeds to the RDO Common Warrants based on the relative fair value of the RDO Common Warrants, Common Stock and Pre-Funded Warrants issued in the Offering. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the purchaser, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 days’ prior notice to the Company. The Registered Direct Offering resulted in gross proceeds to the Company of approximately $2.0 million. The net proceeds to the Company from the Registered Direct Offering are approximately $1.8 million, excluding any proceeds that may be received upon the cash exercise of the RDO Common Warrants, after deducting the financial advisor’s fees and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the Registered Direct Offering for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments and others. The Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties, and termination provisions. Additionally, each of the directors and executive officers of the Company, pursuant to lock-up agreements (the “Lock-Up Agreements”), agreed not to sell or transfer any of the Company securities which they hold, subject to certain exceptions, during the 90-day period following the closing of the Registered Direct Offering. The Purchase Agreement also requires the Company to use commercially reasonable efforts to file a registration statement with the SEC to register the resale by the Purchasers of the shares of Common Stock issuable upon exercise of the RDO Common Warrants within thirty (30) days of the date of the Purchase Agreement. The Company filed this registration statement on Form S-1 (File No. 333-273172), which was declared effective by the SEC on July 19, 2023. On June 7, 2023, the Company also entered into a financial advisory agreement (the “Financial Advisor Agreement”) with A.G.P./Alliance Global Partners (the “Financial Advisor”). Pursuant to the terms of the Financial Advisor Agreement, the Financial Advisor agreed to use its reasonable best efforts to arrange for the sale of the Securities. The Company paid the Financial Advisor a cash fee of $140,000 generated from the sale of the Shares and Pre-Funded Warrants. The Financial Advisor Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Financial Advisor, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of the parties, and termination provisions. ​ Pursuant to the Purchase Agreement, the Company has agreed that, subject to certain exceptions, (i) it will not issue any shares of common stock or securities exercisable or convertible into shares of common stock or to file any registration statement or amendment or supplement thereto for a period of ninety (90) days following the closing of the Offering and that (ii) it will not enter into a variable rate transaction for a period of one hundred eighty (180) days following the closing of the Offering. The Registered Direct Offering was made pursuant to the 2023 Registration Statement, as supplemented by a prospectus supplement dated June 9, 2023. As a result of sales already made through the AGP 2023 Sales Agreement and the Registered Direct Offering, the Company has $3.7 million of remaining availability under the 2023 Registration Statement. ​ Preferred Stock. The Company’s Board of Directors is authorized to issue up to 15,000,000 shares of preferred stock in one or more series, from time to time, with such designations, powers, preferences and rights and such qualifications, limitations and restrictions as may be provided in a resolution or resolutions adopted by the Board of Directors. Series B Preferred Stock. The Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (“Series B Preferred Stock”) with the State of Delaware, which designates 6,900 shares of our preferred stock as Series B Preferred Stock. The Series B Preferred Stock has a stated value of $1 thousand per share and a par value of $0.01 per share. The Series B Preferred Stock includes a beneficial ownership blocker but has no dividend rights (except to the extent dividends are also paid on the common stock). On August 28, 2017, the Company completed an underwritten public offering consisting of the Company’s Series B Preferred Stock and warrants. The conversion price of the Series B Preferred Stock contains a down round feature. The Company will recognize the effect of the down round feature when it is triggered. At that time, the effect would be treated as a deemed dividend and as a reduction of income available to common shareholders in our basic earnings per share calculation. There were no conversions of Series B Preferred Stock during the three and six months ended June 30, 2024 and 2023, respectively. At June 30, 2024 and December 31, 2023, the Company had 6,900 shares of Series B Preferred Stock designated and issued and 47 shares of Series B Preferred Stock outstanding. Based on the stated value of $1 thousand per share and a conversion price of $8.00 per share, the outstanding shares of Series B Preferred Stock at June 30, 2024 were convertible into 5,875 shares of common stock. Common Stock Warrants. The following represents a summary of the warrants outstanding as of June 30, 2024: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Underlying Exercise ​ ​ Issue Year ​ Expiration ​ Shares ​ Price Warrants ​ ​ ​ ​ ​ ​ ​ ​ ​ (1) ​ 2023 ​ December 2028 ​ 444,444 ​ $ 12.60 (1) ​ During the three and six months ended June 30, 2023, 7,419 warrants expired, respectively. The warrants had been issued in connection with transactions that were completed in 2018. During the three and six months ended June 30, 2024, 15,091 warrants expired, respectively. The warrants had been issued in connection with transactions that were completed in 2019. RDO Common Warrants

FAIR VALUE

FAIR VALUE	6 Months Ended
	Jun. 30, 2024
FAIR VALUE [Abstract]
FAIR VALUE	8 FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our condensed consolidated financial statements. FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows: Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities; Level 2—Observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets; and Level 3—Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability. Common Stock Warrant Liabilities. Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated statements of operations. Bridge Note Warrant Liabilities During 2018 and 2019, the Company issued warrants in connection with the issuance of convertible notes. All of these warrants issuances were classified as warrant liabilities (the “Bridge Note Warrant Liabilities”). The Bridge Note Warrant Liabilities are considered Level 3 financial instruments and were valued using the Black Scholes model. During the three months ended June 30, 2024, the last remaining warrants related to Bridge Note Warrant Liabilities expired and thus at June 30, 2024 there were no warrant liabilities to be valued. As of December 31, 2023, assumptions used in the valuation of the Bridge Note Warrant Liabilities include: remaining life to maturity of 0.3 to 0.4 years; volatility rate of 71% to 77%; and risk free rate of 5.33% to 5.40%. During the three and six months ended June 30, 2024, the changes in the fair value of the warrant liabilities measured using significant unobservable inputs (Level 3) were zero. During the three and six months ended June 30, 2023, the changes in the fair value of the warrant liabilities were less than $1 thousand, respectively. ​

EQUITY INCENTIVE PLAN

EQUITY INCENTIVE PLAN	6 Months Ended
	Jun. 30, 2024
EQUITY INCENTIVE PLAN [Abstract]
EQUITY INCENTIVE PLAN	9 The Company currently issues stock awards under its 2017 Stock Option and Incentive Plan, as amended (the “2017 Plan”) which will expire on June 5, 2027. The shares authorized for issuance under the 2017 Plan were 320,699 at June 30, 2024, of which 14,113 were available for future grant. The shares authorized under the 2017 Plan are subject to annual increases on January 1 by 5% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or such lessor number of shares determined by the Company’s Board of Directors or Compensation Committee. During the six months ended June 30, 2024, the shares authorized for issuance increased by 71,006 shares. Stock Options. The Company accounts for all stock-based compensation payments to employees and directors, including grants of employee stock options, at fair value at the date of grant and expenses the benefit in operating expense in the condensed consolidated statements of operations over the service period of the awards. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. The fair value of each stock option granted is estimated on the date of grant using the Black-Scholes option pricing model, which requires various assumptions including estimating stock price volatility, expected life of the stock option, risk free interest rate and estimated forfeiture rate. During the six months ended June 30, 2024, the Company granted stock options to purchase up to 75,862 shares of common stock at a weighted average exercise price of $4.99 per share. These awards have vesting periods of up to four years and had a weighted average grant date fair value of $4.54. The fair value calculation of options granted during the six months ended June 30, 2024 used the following assumptions: risk free interest rate of 3.94% to 4.26%, based on the U.S. Treasury yield in effect at the time of grant; expected life of six years; and volatility of 133% to 139% based on historical volatility of the Company’s common stock over a time that is consistent with the expected life of the option. The following table summarizes stock option activity under our plans during the six months ended June 30, 2024: ​ ​ ​ ​ ​ ​ ​ Number of Weighted-Average ​ ​ Options ​ Exercise Price Outstanding at January 1, 2024 232,744 ​ $ 46.56 Granted 75,862 ​ 4.99 Forfeited (4,581) ​ 19.76 Outstanding at June 30, 2024 304,025 ​ $ 36.59 Exercisable at June 30, 2024 176,276 ​ $ 52.18 ​ As of June 30, 2024, there were 262,591 options that were vested or expected to vest with aggregate intrinsic value of $5 thousand and a remaining weighted average contractual life of 7.6 years. Restricted Stock Awards. Restricted stock awards are subject to vesting restrictions. If a grantee’s service with the Company is terminated prior to vesting of the restricted stock, all unvested shares shall be forfeited and returned to the Company. Upon vesting, the restricted stock award shall no longer be deemed restricted. As of June 30, 2024, there were 2,492 and zero restricted stock awards that were vested and unvested, respectively. There were no restricted stock awards granted during the three and six months ended June 30, 2024 and 2023, respectively. Stock Compensation. For the three and six months ended June 30, 2024, we recorded non-cash stock-based compensation expense for all stock awards of $0.3 million and $0.7 million, respectively, within operating expense in the accompanying statements of operations. For the three and six months ended June 30, 2023, we recorded non-cash stock-based compensation expense for all stock awards of $0.4 million and $0.8 million, respectively, within operating expense in the accompanying statements of operations.

SALES SERVICE REVENUE, NET AND

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE	6 Months Ended
	Jun. 30, 2024
SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE [Abstract]
SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE	10. SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE ASC Topic 606, “Revenue from contracts with customers” The Company follows the guidance of ASC 606 for the recognition of revenue from contracts with customers to transfer goods and services. The Company performed a comprehensive review of its existing revenue arrangements following the five-step model: ​ Step 1: Identification of the contract with the customer. Sub-steps include determining the customer in a contract, initial contract identification and determining if multiple contracts should be combined and accounted for as a single transaction. Step 2: Identify the performance obligation in the contract. Sub-steps include identifying the promised goods and services in the contract and identifying which performance obligations within the contract are distinct. Step 3: Determine the transaction price. Sub-steps include variable consideration, constraining estimates of variable consideration, the existence of a significant financing component in the contract, noncash consideration and consideration payable to a customer. Step 4: Allocate transaction price. Sub-steps include assessing the amount of consideration to which the Company expects to be entitled in exchange for transferring the promised goods or services to the customer. Step 5: Satisfaction of performance obligations. Sub-steps include ascertaining the point in time when an asset is transferred to the customer and when the customer obtains control of the asset upon which time the Company recognizes revenue. ​ Nature of Contracts and Customers The Company’s contracts and related performance obligations are similar for its customers and the sales process for all customers starts upon the receipt of requisition forms from the customers for patient diagnostic testing and the execution of contracts for biomarker testing and clinical research. Payment terms for the services provided are 30 days, unless separately negotiated. ​ Diagnostic testing ​ Control of the laboratory testing services is transferred to the customer at a point in time. As such, the Company recognizes revenue for laboratory testing services at a point in time based on the delivery method (web-portal access or fax) for the patient’s laboratory report, per the contract. ​ Clinical research grants ​ Control of the clinical research services are transferred to the customer over time. The Company will recognize revenue utilizing the “effort based” method, measuring its progress toward complete satisfaction of the performance obligation. ​ Biomarker testing and clinical project services ​ Control of the biomarker testing and clinical project services are transferred to the customer over time. The Company utilizes an “effort based” method of assessing performance and measures progress towards satisfaction of the performance obligation based upon the delivery of results. ​ The Company generates revenue from the provision of diagnostic testing provided to patients, biomarker testing provided to bio-pharma customers and clinical research grants funded by both bio-pharma customers and government health programs. Reagents and other diagnostic products Control of reagents and other diagnostic products are transferred to the customer at a point in time and, as such, the Company recognizes these revenues at a point in time based on the delivery method. These revenues include revenues from reagent sets for our HSRR program and other product sales and are included in product revenue in our condensed consolidated statements of operations. Disaggregation of Revenues by Transaction Type We operate in one business segment and, therefore, the results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Service revenue, net for the three and six months ended June 30, 2024 and 2023 was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended June 30, (dollars in thousands) ​ Diagnostic Testing ​ 2024 2023 Medicaid ​ $ 20 ​ $ 5 Medicare ​ 1,525 ​ 1,165 Self-pay ​ 14 ​ 36 Third party payers ​ 2,348 ​ 1,562 Contract diagnostics and other ​ 2 ​ — Service revenue, net ​ $ 3,909 ​ $ 2,768 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Six Months Ended June 30, (dollars in thousands) ​ Diagnostic Testing ​ 2024 2023 Medicaid ​ $ 25 ​ $ 13 Medicare ​ 2,616 ​ 2,045 Self-pay ​ 32 ​ 116 Third party payers ​ 4,053 ​ 2,662 Contract diagnostics and other ​ 4 ​ — Service revenue, net ​ $ 6,730 ​ $ 4,836 ​ ​ Revenue from the Medicare and Medicaid programs account for a portion of the Company’s patient diagnostic service revenue. Laws and regulations governing those programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience. The Company does not typically enter arrangements where multiple contracts can be combined as the terms regarding services are generally found within a single agreement/requisition form. The Company derives its revenues from the following types of transactions: diagnostic testing (“Diagnostic”), revenues from the Company’s ICP technology and bio-pharma projects encompassing genetic diagnostics (collectively “Biomarker”), revenues from clinical research grants from state and federal research programs and diagnostic product sales, including revenues from equipment leases and reagent sales associated with our HSRR program. Deferred revenue Deferred revenue, or unearned revenue, refers to advance payments for products or services that are to be delivered in the future. The Company records such prepayment of unearned revenue as a liability, as revenue that has not yet been earned, but represents products or services that are owed to a customer. As the product or service is delivered over time, the Company recognizes the appropriate amount of revenue from deferred revenue. For the periods ended June 30, 2024 and December 31, 2023, the deferred revenue was $0.3 million and $0.1 million, respectively. Contractual Allowances and Adjustments We are reimbursed by payers for services we provide. Payments for services covered by payers average less than billed charges. We monitor revenue and receivables from payers and record an estimated contractual allowance for certain revenue and receivable balances as of the revenue recognition date to properly account for anticipated differences between amounts estimated in our billing system and amounts ultimately reimbursed by payers. Accordingly, the total revenue and receivables reported in our condensed consolidated financial statements are recorded at the amounts expected to be received from these payers. For service revenue, the contractual allowance is estimated based on several criteria, including unbilled claims, historical trends based on actual claims paid, current contract and reimbursement terms and changes in customer base and payer/product mix. The billing functions for the remaining portion of our revenue are contracted and fixed fees for specific services and are recorded without an allowance for contractual discounts . The following table presents our revenues initially recognized for each associated payer class during the three and six months ended June 30, 2024 and 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended June 30, (dollars in thousands) ​ ​ ​ Contractual Allowances and ​ Revenues, net of Contractual ​ ​ Gross Revenues ​ adjustments ​ Allowances and adjustments ​ 2024 2023 2024 2023 2024 2023 Medicaid ​ $ 20 ​ $ 5 ​ $ — ​ $ — ​ $ 20 ​ $ 5 Medicare ​ 1,525 ​ 1,165 ​ — ​ — ​ 1,525 ​ 1,165 Self-pay ​ 14 ​ 36 ​ — ​ — ​ 14 ​ 36 Third party payers ​ 7,961 ​ 5,442 ​ (5,613) ​ (3,880) ​ 2,348 ​ 1,562 Contract diagnostics and other ​ 2 ​ — ​ — ​ — ​ 2 ​ — ​ ​ 9,522 ​ 6,648 ​ (5,613) ​ (3,880) ​ 3,909 ​ 2,768 Product ​ 598 ​ 877 ​ — ​ — ​ 598 ​ 877 ​ ​ $ 10,120 ​ $ 7,525 ​ $ (5,613) ​ $ (3,880) ​ $ 4,507 ​ $ 3,645 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Six Months Ended June 30, (dollars in thousands) ​ ​ ​ Contractual Allowances and ​ Revenues, net of Contractual ​ ​ Gross Revenues ​ adjustments ​ Allowances and adjustments ​ 2024 2023 2024 2023 2024 2023 Medicaid ​ $ 25 ​ $ 13 ​ $ — ​ $ — ​ $ 25 ​ $ 13 Medicare ​ 2,616 ​ 2,045 ​ — ​ — ​ 2,616 ​ 2,045 Self-pay ​ 32 ​ 116 ​ — ​ — ​ 32 ​ 116 Third party payers ​ 13,929 ​ 9,277 ​ (9,876) ​ (6,615) ​ 4,053 ​ 2,662 Contract diagnostics ​ 4 ​ — ​ — ​ — ​ 4 ​ — ​ ​ 16,606 ​ 11,451 ​ (9,876) ​ (6,615) ​ 6,730 ​ 4,836 Product ​ 1,255 ​ 1,638 ​ — ​ — ​ 1,255 ​ 1,638 ​ ​ $ 17,861 ​ $ 13,089 ​ $ (9,876) ​ $ (6,615) ​ $ 7,985 ​ $ 6,474 ​ ​ Allowance for Credit Losses The Company provides for a general allowance for collectability of services when recording net sales. The Company has adopted the policy of recognizing net sales to the extent it expects to collect that amount. Reference is made to FASB 954-605-45-5 and ASU 2011-07, Health Care Entities: Presentation and Disclosure of Patient Service Revenue, Provision for Credit Loss, and the Allowance for Credit Losses. The change in the allowance for credit losses is directly related to the increase in patient service revenues. The following table presents our reported revenues net of the collection allowance and adjustments for the three and six months ended June 30, 2024 and 2023. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended June 30, ​ ​ Revenues, net of ​ ​ ​ (dollars in thousands) ​ Contractual Allowances ​ Allowances for credit ​ ​ ​ and adjustments ​ losses ​ Total ​ 2024 2023 2024 2023 2024 2023 Medicaid ​ $ 20 ​ $ 5 ​ $ (7) ​ $ (2) ​ $ 13 ​ $ 3 Medicare ​ 1,525 ​ 1,165 ​ (23) ​ (23) ​ 1,502 ​ 1,142 Self-pay ​ 14 ​ 36 ​ (1) ​ (4) ​ 13 ​ 32 Third party payers ​ 2,348 ​ 1,562 ​ (35) ​ (83) ​ 2,313 ​ 1,479 Contract diagnostics and other ​ 2 ​ — ​ — ​ — ​ 2 ​ — ​ ​ 3,909 ​ 2,768 ​ (66) ​ (112) ​ 3,843 ​ 2,656 Product ​ 598 ​ 877 ​ — ​ — ​ 598 ​ 877 ​ ​ $ 4,507 ​ $ 3,645 ​ $ (66) ​ $ (112) ​ $ 4,441 ​ $ 3,533 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Six Months Ended June 30, ​ ​ Revenues, net of ​ ​ ​ (dollars in thousands) ​ Contractual Allowances ​ Allowances for credit ​ ​ ​ and adjustments ​ losses ​ Total ​ 2024 2023 2024 2023 2024 2023 Medicaid ​ $ 25 ​ $ 13 ​ $ (9) ​ $ (6) ​ $ 16 ​ $ 7 Medicare ​ 2,616 ​ 2,045 ​ (39) ​ (23) ​ 2,577 ​ 2,022 Self-pay ​ 32 ​ 116 ​ (3) ​ (12) ​ 29 ​ 104 Third party payers ​ 4,053 ​ 2,662 ​ (61) ​ (83) ​ 3,992 ​ 2,579 Contract diagnostics and other ​ 4 ​ — ​ — ​ — ​ 4 ​ — ​ ​ 6,730 ​ 4,836 ​ (112) ​ (124) ​ 6,618 ​ 4,712 Product ​ 1,255 ​ 1,638 ​ — ​ — ​ 1,255 ​ 1,638 ​ ​ $ 7,985 ​ $ 6,474 ​ $ (112) ​ $ (124) ​ $ 7,873 ​ $ 6,350 ​ ​ Costs to Obtain or Fulfill a Customer Contract Sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in operating expenses in the condensed consolidated statements of operations. Shipping and handling costs are comprised of inbound and outbound freight and associated labor. The Company accounts for shipping and handling activities related to contracts with customers as fulfillment costs which are included in cost of sales in the condensed consolidated statements of operations. Accounts Receivable The Company has provided an allowance for potential credit losses, which has been determined based on management’s industry experience. The Company grants credit without collateral to its patients, most of who are insured under third party payer agreements. The following summarizes the mix of receivables outstanding related to payer categories: ​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) June 30, 2024 December 31, 2023 Medicaid ​ $ 20 ​ $ 25 Medicare ​ 2,034 ​ 1,561 Self-pay ​ 196 ​ 229 Third party payers ​ 1,293 ​ 1,641 Contract diagnostic services, product and other ​ 248 ​ 417 ​ ​ $ 3,791 ​ $ 3,873 Less allowance for credit losses ​ (2,684) ​ (2,572) Accounts receivable, net ​ $ 1,107 ​ $ 1,301 ​ The following table presents the roll-forward of the allowance for credit losses for the six months ended June 30, 2024. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Allowance for ​ ​ ​ ​ ​ Credit (dollars in thousands) ​ ​ ​ ​ Losses Balance, January 1, 2024 ​ ​ $ (2,572) Provision for credit losses: ​ ​ Medicaid ​ $ (9) ​ Medicare ​ (39) ​ Self-pay ​ ​ (3) ​ ​ ​ Third party payers ​ (61) ​ ​ ​ (112) ​ Credit loss expense ​ $ — ​ Total charges ​ ​ (112) Balance, June 30, 2024 ​ ​ $ (2,684) ​ Customer Revenue and Accounts Receivable Concentration Our customers are oncologists, hospitals, reference laboratories, physician-office laboratories, and pharma and biotech companies. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net sales ​ ​ Net sales ​ ​ Accounts receivable, as of ​ ​ ​ Three Months Ended ​ ​ Six Months Ended ​ ​ ​ ​ ​ ​ June 30, ​ ​ June 30, ​ ​ June 30, ​ December 31, ​ ​ ​ 2024 ​ 2023 ​ ​ 2024 ​ 2023 ​ ​ 2024 ​ 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Customer A ​ * ​ 11 % ​ * ​ 14 % ​ 12 % * ​ Customer B ​ * ​ * ​ ​ * ​ * ​ ​ * ​ 13 % Customer C ​ 12 % * ​ ​ * ​ * ​ ​ 21 % * ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ * represents less than 10% ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2024
SUBSEQUENT EVENTS [Abstract]
SUBSEQUENT EVENTS	11. SUBSEQUENT EVENTS The Company has evaluated events and transactions subsequent to June 30, 2024 through the date of this Quarterly Report on Form 10-Q, and there are no other events to report other than what has been disclosed in the condensed consolidated financial statements. ​ ​

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2024
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Basis of Presentation	Basis of Presentation. The accompanying condensed consolidated financial statements are presented in conformity with GAAP. As required under GAAP, pursuant to a 1-for- 20 , unless otherwise indicated, the Company has adjusted all share amounts, per share data, share prices, exercise prices and conversion rates set forth in these notes and the accompanying condensed consolidated financial statements.
Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements. In June 2022, the Financial Accounting Standards Board (the “FASB”) issued ASU 2022-03, Fair Value Measurement (Topic 820) (“ASU 2022-03”). The amendments in ASU 2022-03 clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments in this Update also require additional disclosures for equity securities subject to contractual sale restrictions. The Company adopted this guidance on January 1, 2024. The adoption of this standard was not material to our condensed consolidated financial statements. In August 2020, the FASB issued ASU 2020-06 “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity The adoption of this standard was not material to our condensed consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis, primarily through enhanced disclosures of significant segment expenses. The guidance will be effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 and requires retrospective application to all periods presented upon adoption, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its condensed consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09—Income Taxes (Topic 740)—Improvements to Income Tax Disclosures (“ASU 2023-09”) which is intended to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires additional disaggregation of the reconciliation between the statutory and effective tax rate for an entity and of income taxes paid, both of which are disclosures required by current GAAP. The amendments improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. The amendments in ASU 2023-09 apply to all entities that are subject to Topic 740, Income Taxes. For public business entities, the amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. ASU 2023-09 is effective for the Company beginning January 1, 2025. Adoption of ASU 2023-09 is expected to enhance the usefulness of income tax disclosures and is not expected to have a material impact on the Company’s financial position, results of operations or cash flow.
Loss Per Share	Loss Per Share. Basic loss per share is calculated based on the weighted-average number of common shares (including pre-funded warrants) outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Shares of the Company’s common stock underlying pre-funded warrants are included in the calculation of basic and diluted loss per share due to the negligible exercise price of the pre-funded warrants. Options, warrants and conversion rights pertaining to 754,344 and 709,159 shares of our common stock have been excluded from the computation of diluted loss per share at June 30, 2024 and 2023, respectively, because the effect is anti-dilutive due to the net loss. The following table summarizes the outstanding securities not included in the computation of diluted net loss per share: ​ ​ ​ ​ ​ ​ ​ June 30, ​ 2024 2023 Stock options 304,025 231,802 Warrants 444,444 471,482 Preferred stock 5,875 5,875 Total 754,344 709,159 ​

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2024
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Schedule of outstanding securities not included in the computation of diluted net loss per share	The following table summarizes the outstanding securities not included in the computation of diluted net loss per share: ​ ​ ​ ​ ​ ​ ​ June 30, ​ 2024 2023 Stock options 304,025 231,802 Warrants 444,444 471,482 Preferred stock 5,875 5,875 Total 754,344 709,159 ​

LONG-TERM DEBT (Tables)

LONG-TERM DEBT (Tables)	6 Months Ended
	Jun. 30, 2024
LONG-TERM DEBT [Abstract]
Schedule of debt	Long-term debt consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ Dollars in Thousands ​ June 30, 2024 December 31, 2023 Connecticut Department of Economic and Community Development (DECD) ​ $ 131 ​ $ 146 DECD debt issuance costs ​ (11) ​ (12) Financed insurance loan ​ — ​ 207 Business loan agreement ​ ​ 221 ​ ​ — Total long-term debt ​ 341 ​ 341 Current portion of long-term debt ​ (249) ​ (235) Long-term debt, net of current maturities ​ $ 92 ​ $ 106

ACCRUED EXPENSES AND OTHER CURR

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES. (Tables)	6 Months Ended
	Jun. 30, 2024
ACCRUED EXPENSES [Abstract]
Schedule of accrued expenses	Accrued expenses at June 30, 2024 and December 31, 2023 are as follows: ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) June 30, 2024 December 31, 2023 Accrued expenses ​ $ 668 ​ $ 764 Accrued compensation ​ 993 ​ 754 Accrued franchise, property and sales and use taxes ​ ​ 181 ​ ​ 287 CHC temporary funding assistance ​ ​ 1,057 ​ ​ — Accrued interest ​ 19 ​ 19 ​ ​ $ 2,918 ​ $ 1,824

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2024
LEASES [Abstract]
Summary of balance sheet presentation of our operating and finance leases	​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) ​ ​ ​ ​ ​ ​ Classification on the Condensed Consolidated Balance Sheet ​ June 30, 2024 ​ December 31, 2023 Assets: ​ ​ ​ ​ ​ ​ Operating lease right-of-use assets, net ​ $ 498 ​ $ 612 Finance lease right-of-use assets, net (1) ​ ​ 372 ​ ​ 174 Total lease assets ​ $ 870 ​ $ 786 ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ ​ ​ Current: ​ ​ ​ ​ ​ ​ Current maturities of operating lease liabilities ​ $ 208 ​ $ 218 Current maturities of finance lease liabilities ​ ​ 105 ​ ​ 132 Noncurrent: ​ ​ ​ ​ ​ ​ Operating lease liabilities, less current maturities ​ ​ 301 ​ ​ 407 Finance lease liabilities, less current maturities ​ ​ 215 ​ ​ 18 Total lease liabilities ​ $ 829 ​ $ 775 (1) As of June 30, 2024 and December 31, 2023, finance lease right-of-use assets included zero , respectively, of assets related to finance leases associated with the HSRR program.
Summary of estimated future minimum lease payments for operating leases	As of June 30, 2024, the estimated future minimum lease payments, excluding non-lease components, are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) Operating Leases ​ Finance Leases ​ Total ​ ​ ​ June 30, ​ ​ June 30, ​ ​ June 30, ​ ​ ​ 2024 ​ ​ 2024 ​ ​ 2024 2024 (remaining) ​ $ 120 ​ $ 74 ​ $ 194 2025 ​ 224 ​ 134 ​ 358 2026 ​ 214 ​ 95 ​ 309 2027 ​ — ​ ​ 69 ​ 69 2028 ​ ​ — ​ ​ 29 ​ ​ 29 Total lease obligations ​ 558 ​ 401 ​ 959 Less: Amount representing interest ​ (49) ​ (81) ​ (130) Present value of net minimum lease obligations ​ 509 ​ 320 ​ 829 Less, current portion ​ (208) ​ (105) ​ (313) Long term portion ​ $ 301 ​ $ 215 ​ $ 516
Summary of estimated future minimum lease payments for finance leases	As of June 30, 2024, the estimated future minimum lease payments, excluding non-lease components, are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) Operating Leases ​ Finance Leases ​ Total ​ ​ ​ June 30, ​ ​ June 30, ​ ​ June 30, ​ ​ ​ 2024 ​ ​ 2024 ​ ​ 2024 2024 (remaining) ​ $ 120 ​ $ 74 ​ $ 194 2025 ​ 224 ​ 134 ​ 358 2026 ​ 214 ​ 95 ​ 309 2027 ​ — ​ ​ 69 ​ 69 2028 ​ ​ — ​ ​ 29 ​ ​ 29 Total lease obligations ​ 558 ​ 401 ​ 959 Less: Amount representing interest ​ (49) ​ (81) ​ (130) Present value of net minimum lease obligations ​ 509 ​ 320 ​ 829 Less, current portion ​ (208) ​ (105) ​ (313) Long term portion ​ $ 301 ​ $ 215 ​ $ 516
Schedule of other information	​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2024 ​ 2023 Weighted-average remaining lease term (years): ​ ​ ​ Operating leases 2.4 ​ 2.8 Finance leases 3.0 ​ 2.0 Weighted-average discount rate: ​ ​ ​ Operating leases 8.00% ​ 8.00% Finance leases 13.62% ​ 10.63%

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	6 Months Ended
	Jun. 30, 2024
STOCKHOLDERS' EQUITY [Abstract]
Schedule of stockholders' equity, including warrants and rights	The following represents a summary of the warrants outstanding as of June 30, 2024: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Underlying Exercise ​ ​ Issue Year ​ Expiration ​ Shares ​ Price Warrants ​ ​ ​ ​ ​ ​ ​ ​ ​ (1) ​ 2023 ​ December 2028 ​ 444,444 ​ $ 12.60 (1)

EQUITY INCENTIVE PLAN (Tables)

EQUITY INCENTIVE PLAN (Tables)	6 Months Ended
	Jun. 30, 2024
EQUITY INCENTIVE PLAN [Abstract]
Summary of stock option activity	The following table summarizes stock option activity under our plans during the six months ended June 30, 2024: ​ ​ ​ ​ ​ ​ ​ Number of Weighted-Average ​ ​ Options ​ Exercise Price Outstanding at January 1, 2024 232,744 ​ $ 46.56 Granted 75,862 ​ 4.99 Forfeited (4,581) ​ 19.76 Outstanding at June 30, 2024 304,025 ​ $ 36.59 Exercisable at June 30, 2024 176,276 ​ $ 52.18

SALES SERVICE REVENUE, NET AN_2

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Tables)	6 Months Ended
	Jun. 30, 2024
SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE [Abstract]
Schedule of Net Revenues	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended June 30, (dollars in thousands) ​ Diagnostic Testing ​ 2024 2023 Medicaid ​ $ 20 ​ $ 5 Medicare ​ 1,525 ​ 1,165 Self-pay ​ 14 ​ 36 Third party payers ​ 2,348 ​ 1,562 Contract diagnostics and other ​ 2 ​ — Service revenue, net ​ $ 3,909 ​ $ 2,768 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Six Months Ended June 30, (dollars in thousands) ​ Diagnostic Testing ​ 2024 2023 Medicaid ​ $ 25 ​ $ 13 Medicare ​ 2,616 ​ 2,045 Self-pay ​ 32 ​ 116 Third party payers ​ 4,053 ​ 2,662 Contract diagnostics and other ​ 4 ​ — Service revenue, net ​ $ 6,730 ​ $ 4,836 ​ ​
Schedule of Gross to Net Sales Adjustments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended June 30, (dollars in thousands) ​ ​ ​ Contractual Allowances and ​ Revenues, net of Contractual ​ ​ Gross Revenues ​ adjustments ​ Allowances and adjustments ​ 2024 2023 2024 2023 2024 2023 Medicaid ​ $ 20 ​ $ 5 ​ $ — ​ $ — ​ $ 20 ​ $ 5 Medicare ​ 1,525 ​ 1,165 ​ — ​ — ​ 1,525 ​ 1,165 Self-pay ​ 14 ​ 36 ​ — ​ — ​ 14 ​ 36 Third party payers ​ 7,961 ​ 5,442 ​ (5,613) ​ (3,880) ​ 2,348 ​ 1,562 Contract diagnostics and other ​ 2 ​ — ​ — ​ — ​ 2 ​ — ​ ​ 9,522 ​ 6,648 ​ (5,613) ​ (3,880) ​ 3,909 ​ 2,768 Product ​ 598 ​ 877 ​ — ​ — ​ 598 ​ 877 ​ ​ $ 10,120 ​ $ 7,525 ​ $ (5,613) ​ $ (3,880) ​ $ 4,507 ​ $ 3,645 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Six Months Ended June 30, (dollars in thousands) ​ ​ ​ Contractual Allowances and ​ Revenues, net of Contractual ​ ​ Gross Revenues ​ adjustments ​ Allowances and adjustments ​ 2024 2023 2024 2023 2024 2023 Medicaid ​ $ 25 ​ $ 13 ​ $ — ​ $ — ​ $ 25 ​ $ 13 Medicare ​ 2,616 ​ 2,045 ​ — ​ — ​ 2,616 ​ 2,045 Self-pay ​ 32 ​ 116 ​ — ​ — ​ 32 ​ 116 Third party payers ​ 13,929 ​ 9,277 ​ (9,876) ​ (6,615) ​ 4,053 ​ 2,662 Contract diagnostics ​ 4 ​ — ​ — ​ — ​ 4 ​ — ​ ​ 16,606 ​ 11,451 ​ (9,876) ​ (6,615) ​ 6,730 ​ 4,836 Product ​ 1,255 ​ 1,638 ​ — ​ — ​ 1,255 ​ 1,638 ​ ​ $ 17,861 ​ $ 13,089 ​ $ (9,876) ​ $ (6,615) ​ $ 7,985 ​ $ 6,474
Schedule of Reported Revenues Net of Collection Allowance	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended June 30, ​ ​ Revenues, net of ​ ​ ​ (dollars in thousands) ​ Contractual Allowances ​ Allowances for credit ​ ​ ​ and adjustments ​ losses ​ Total ​ 2024 2023 2024 2023 2024 2023 Medicaid ​ $ 20 ​ $ 5 ​ $ (7) ​ $ (2) ​ $ 13 ​ $ 3 Medicare ​ 1,525 ​ 1,165 ​ (23) ​ (23) ​ 1,502 ​ 1,142 Self-pay ​ 14 ​ 36 ​ (1) ​ (4) ​ 13 ​ 32 Third party payers ​ 2,348 ​ 1,562 ​ (35) ​ (83) ​ 2,313 ​ 1,479 Contract diagnostics and other ​ 2 ​ — ​ — ​ — ​ 2 ​ — ​ ​ 3,909 ​ 2,768 ​ (66) ​ (112) ​ 3,843 ​ 2,656 Product ​ 598 ​ 877 ​ — ​ — ​ 598 ​ 877 ​ ​ $ 4,507 ​ $ 3,645 ​ $ (66) ​ $ (112) ​ $ 4,441 ​ $ 3,533 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Six Months Ended June 30, ​ ​ Revenues, net of ​ ​ ​ (dollars in thousands) ​ Contractual Allowances ​ Allowances for credit ​ ​ ​ and adjustments ​ losses ​ Total ​ 2024 2023 2024 2023 2024 2023 Medicaid ​ $ 25 ​ $ 13 ​ $ (9) ​ $ (6) ​ $ 16 ​ $ 7 Medicare ​ 2,616 ​ 2,045 ​ (39) ​ (23) ​ 2,577 ​ 2,022 Self-pay ​ 32 ​ 116 ​ (3) ​ (12) ​ 29 ​ 104 Third party payers ​ 4,053 ​ 2,662 ​ (61) ​ (83) ​ 3,992 ​ 2,579 Contract diagnostics and other ​ 4 ​ — ​ — ​ — ​ 4 ​ — ​ ​ 6,730 ​ 4,836 ​ (112) ​ (124) ​ 6,618 ​ 4,712 Product ​ 1,255 ​ 1,638 ​ — ​ — ​ 1,255 ​ 1,638 ​ ​ $ 7,985 ​ $ 6,474 ​ $ (112) ​ $ (124) ​ $ 7,873 ​ $ 6,350 ​ ​
Schedule of Receivables	​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) June 30, 2024 December 31, 2023 Medicaid ​ $ 20 ​ $ 25 Medicare ​ 2,034 ​ 1,561 Self-pay ​ 196 ​ 229 Third party payers ​ 1,293 ​ 1,641 Contract diagnostic services, product and other ​ 248 ​ 417 ​ ​ $ 3,791 ​ $ 3,873 Less allowance for credit losses ​ (2,684) ​ (2,572) Accounts receivable, net ​ $ 1,107 ​ $ 1,301
Schedule of Allowance for Doubtful Accounts	The following table presents the roll-forward of the allowance for credit losses for the six months ended June 30, 2024. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Allowance for ​ ​ ​ ​ ​ Credit (dollars in thousands) ​ ​ ​ ​ Losses Balance, January 1, 2024 ​ ​ $ (2,572) Provision for credit losses: ​ ​ Medicaid ​ $ (9) ​ Medicare ​ (39) ​ Self-pay ​ ​ (3) ​ ​ ​ Third party payers ​ (61) ​ ​ ​ (112) ​ Credit loss expense ​ $ — ​ Total charges ​ ​ (112) Balance, June 30, 2024 ​ ​ $ (2,684)
Schedule of Customer Revenue and Accounts Receivable Concentrations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net sales ​ ​ Net sales ​ ​ Accounts receivable, as of ​ ​ ​ Three Months Ended ​ ​ Six Months Ended ​ ​ ​ ​ ​ ​ June 30, ​ ​ June 30, ​ ​ June 30, ​ December 31, ​ ​ ​ 2024 ​ 2023 ​ ​ 2024 ​ 2023 ​ ​ 2024 ​ 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Customer A ​ * ​ 11 % ​ * ​ 14 % ​ 12 % * ​ Customer B ​ * ​ * ​ ​ * ​ * ​ ​ * ​ 13 % Customer C ​ 12 % * ​ ​ * ​ * ​ ​ 21 % * ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ * represents less than 10% ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

BUSINESS DESCRIPTION (Narrative

BUSINESS DESCRIPTION (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended		39 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Apr. 08, 2024	Dec. 31, 2023	Apr. 14, 2023	Apr. 13, 2020
Business Acquisition [Line Items]
Net loss	$ 3,300,000		$ 3,300,000		$ 3,300,000
Net cash used in operating activities			(167,000)	$ (2,777,000)
Accumulated deficit	(101,449,000)		(101,449,000)		(101,449,000)		$ (98,150,000)
Working capital	1,200,000		1,200,000		1,200,000
Aggregate authorized offering price						$ 1,061,478,000
Proceeds from issuance of common stock			78,000	$ 2,245,000
Amount available for future sale of shares pursuant to the sales agreement	1,000,000		1,000,000		1,000,000
AGP 2023 Sales Agreement
Business Acquisition [Line Items]
Aggregate authorized offering price						1,061,478		$ 5,800,000
Proceeds from issuance of common stock	$ 11,000		$ 100,000
Shares issued (in shares)	1,655	25	11,822	25
Amount available for future sale of shares pursuant to the sales agreement	$ 3,700,000		$ 3,700,000		3,700,000	$ 1,000,000
At The Market Offering Agreement | AGP
Business Acquisition [Line Items]
Aggregate authorized offering price									$ 50,000,000
Proceeds from issuance of common stock		$ 100,000		$ 500,000	$ 15,600,000
Shares issued (in shares)		3,636		30,827	260,128
Payments of stock issuance costs					$ 500,000
Maximum | AGP 2023 Sales Agreement
Business Acquisition [Line Items]
Aggregate authorized offering price								$ 5,800,000
Proceeds from issuance of common stock		$ 1,000		$ 1,000

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)		6 Months Ended
	Sep. 21, 2023	Jun. 30, 2024 shares	Jun. 30, 2023 shares
Summary of Significant Accounting Policies [Line Items]
Reverse stock split	0.05
Securities not included in the computation of diluted net loss per share (in shares)		754,344	709,159

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Outstanding Securities) (Details) - shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities not included in the computation of diluted net loss per share (in shares)	754,344	709,159
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities not included in the computation of diluted net loss per share (in shares)	304,025	231,802
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities not included in the computation of diluted net loss per share (in shares)	444,444	471,482
Preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities not included in the computation of diluted net loss per share (in shares)	5,875	5,875

LONG-TERM DEBT (Schedule of Deb

LONG-TERM DEBT (Schedule of Debt) (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Total long-term debt	$ 341	$ 341
Current portion of long-term debt	(249)	(235)
Long-term debt, net of current maturities	92	106
Connecticut Department of Economic and Community Development (DECD) [Member]
Debt Instrument [Line Items]
Total long-term debt	131	146
Debt issuance cost	(11)	(12)
Financed Insurance Loan [Member]
Debt Instrument [Line Items]
Total long-term debt		207
Current portion of long-term debt	0	$ (200)
Business Loan Agreement [Member]
Debt Instrument [Line Items]
Total long-term debt	$ 221

LONG-TERM DEBT (Narrative) (Det

LONG-TERM DEBT (Narrative) (Details) - USD ($)		3 Months Ended		6 Months Ended
	Jan. 08, 2018	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Jul. 31, 2023
Debt Instrument [Line Items]
Current maturities of long-term debt, less debt issuance costs		$ 249,000		$ 249,000		$ 235,000
Financed Insurance Loan [Member]
Debt Instrument [Line Items]
Current maturities of long-term debt, less debt issuance costs		0		$ 0		$ 200,000
Interest rate (as a percent)							9.99%
Debt instrument, face amount							$ 400,000
Term loan | Department of Economic and Community Development (DECD) Loan [Member]
Debt Instrument [Line Items]
Proceeds from long-term debt	$ 300,000
Debt instrument, term	10 years
Debt instrument, maturity date	Dec. 31, 2027			May 31, 2028
Interest rate (as a percent)	3.25%
Term loan | Department of Economic and Community Development (DECD) Loan [Member] | Maximum [Member]
Debt Instrument [Line Items]
Amortization of debt issuance cost		$ 1,000	$ 1,000	$ 1,000	$ 1,000

LONG-TERM DEBT (Financed Insura

LONG-TERM DEBT (Financed Insurance Loan) (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Jul. 31, 2023
Debt Instrument [Line Items]
Total debt	$ 341	$ 341
Financed Insurance Loan [Member]
Debt Instrument [Line Items]
Debt instrument, face amount			$ 400
Interest rate (as a percent)			9.99%
Total debt		$ 207

LONG-TERM DEBT (Business Loan A

LONG-TERM DEBT (Business Loan Agreement) (Details) - USD ($)	May 01, 2024	Jun. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Current maturities of long-term debt, less debt issuance costs		$ 249,000	$ 235,000
Loan Agreement
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 250,000
Debt Instrument, Term	1 year
Interest rate (as a percent)	20%
Debt Instrument, Periodic Payment	$ 5,769
Convertible notes	300,000
Additional borrowing capacity	250,000
Current maturities of long-term debt, less debt issuance costs		$ 200,000	$ 0
Loan Agreement | Default Fees
Debt Instrument [Line Items]
Fee	$ 15,000

ACCRUED EXPENSES AND OTHER CU_2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES. (Accrued Expenses) (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Accrued expenses	$ 668	$ 764
Accrued compensation	993	754
Accrued franchise, property and sales and use taxes	181	287
CHC temporary funding assistance	1,057
Accrued interest	19	19
Accrued expenses	2,918	$ 1,824
Maximum [Member]
Amount received from Temporary Assistance Program	$ 1,100

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($) $ in Millions	Feb. 06, 2017	Jun. 30, 2024	Dec. 31, 2023
Loss Contingencies [Line Items]
Other Commitment		$ 0.9
CPA Global
Loss Contingencies [Line Items]
Loss contingency, damages sought	$ 0.2
CPA Global | Maximum [Member]
Loss Contingencies [Line Items]
Loss contingency accrual		$ 0.1	$ 0.1

LEASES - Narrative (Details)

LEASES - Narrative (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) item	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Lessee, Lease, Description [Line Items]
Operating leases			$ 100	$ 100
Operating lease right-of-use assets obtained in exchange for operating lease obligations			0	58
Finance lease right-of-use assets obtained in exchange for finance lease obligations			205	0
Operating lease right-of-use assets, net	$ 498		498		$ 612
Finance lease ROU assets			$ 35	43
Minimum [Member]
Lessee, Lease, Description [Line Items]
Facility leases | item			1
Renewal term	1 year		1 year
Maximum [Member]
Lessee, Lease, Description [Line Items]
Renewal term	5 years		5 years
HemeScreen Reagent Rental [Member]
Lessee, Lease, Description [Line Items]
Finance lease ROU assets	$ 0	$ 0	$ 0	$ 0
Net investment in leased assets	$ 100		$ 100		$ 100

LEASES - Operating and Financin

LEASES - Operating and Financing leases (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Balance sheet presentation of our operating and financing leases
Operating lease right-of-use assets, net	$ 498	$ 612
Finance lease right-of-use assets, net	372	174
Total lease assets	870	786
Current maturities of operating lease liabilities	208	218
Current maturities of finance lease liabilities	105	132
Operating lease liabilities, less current maturities	301	407
Finance lease liabilities, less current maturities	215	18
Present value of net minimum lease obligations	829	775
HemeScreen Reagent Rental [Member]
Balance sheet presentation of our operating and financing leases
Finance lease right-of-use assets, net	$ 0	$ 0

LEASES - Future Minimum Lease P

LEASES - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Operating leases, estimated future minimum lease payments
2024 (remaining)	$ 120
2025	224
2026	214
Total lease obligations	558
Less: Amount representing interest	(49)
Present value of net minimum lease obligations	509
Less, current portion	(208)	$ (218)
Long term portion	301	407
Finance leases, estimated future minimum lease payments
2024 (remaining)	74
2025	134
2026	95
2027	69
2028	29
Total lease obligations	401
Less: Amount representing interest	(81)
Present value of net minimum lease obligations	320
Less, current portion	(105)	(132)
Long term portion	215	18
2024 (remaining)	194
2025	358
2026	309
2027	69
2028	29
Total lease obligations	959
Less: Amount representing interest	(130)
Present value of net minimum lease obligations	829	$ 775
Less, current portion	(313)
Long term portion	$ 516

LEASES - Other Information (Det

LEASES - Other Information (Details)	Jun. 30, 2024	Dec. 31, 2023
LEASES [Abstract]
Operating leases (in years)	2 years 4 months 24 days	2 years 9 months 18 days
Finance leases (in years)	3 years	2 years
Operating leases discount rate	8%	8%
Finance leases discount rate	13.62%	10.63%

LEASES - Operating and Financ_2

LEASES - Operating and Financing Lease Cost (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Lessee, Lease, Description [Line Items]
Operating lease costs	$ 0.1	$ 0.1	$ 0.1	$ 0.2
Maximum [Member]
Lessee, Lease, Description [Line Items]
Short-term lease costs	0.1	0.1	0.1	0.1
Finance lease amortization and interest expenses	$ 0.1	$ 0.1	$ 0.1	$ 0.1

STOCKHOLDERS' EQUITY (Common St

STOCKHOLDERS' EQUITY (Common Stock) (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024	Dec. 31, 2023	Dec. 20, 2018	Dec. 19, 2018
Class of Stock [Line Items]
Common stock, shares authorized (in shares)	150,000,000	150,000,000	150,000,000	250,000,000	150,000,000
Issuance of common stock for consulting services	$ 251	$ 251
Common Stock
Class of Stock [Line Items]
Issuance of common stock for consulting services (in shares)	37,593	37,593
Issuance of common stock for consulting services	$ 300	$ 300

STOCKHOLDERS' EQUITY (At The Ma

STOCKHOLDERS' EQUITY (At The Market Offering Agreement) (Details) - USD ($)			3 Months Ended		6 Months Ended		39 Months Ended
	Apr. 14, 2023	Apr. 02, 2021	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Apr. 08, 2024	Dec. 31, 2023	Apr. 13, 2020
Class of Stock [Line Items]
Common stock, par value (in $ per share)			$ 0.01		$ 0.01		$ 0.01		$ 0.01
Aggregate authorized offering price								$ 1,061,478,000
Proceeds from issuance of common stock					$ 78,000	$ 2,245,000
Amount available for future sale of shares pursuant to the sales agreement			$ 1,000,000		1,000,000		$ 1,000,000
At The Market Offering Agreement | AGP
Class of Stock [Line Items]
Common stock, par value (in $ per share)		$ 0.01
Aggregate sales proceeds of common stock		$ 22,000,000
Aggregate authorized offering price										$ 50,000,000
Percentage of cash fee		3%
Proceeds from issuance of common stock				$ 100,000		$ 500,000	$ 15,600,000
Shares issued (in shares)				3,636		30,827	260,128
Payments of Stock Issuance Costs							$ 500,000
AGP 2023 Sales Agreement
Class of Stock [Line Items]
Aggregate authorized offering price	$ 5,800,000							1,061,478
Percentage of cash fee	3%
Proceeds from issuance of common stock			$ 11,000		$ 100,000
Shares issued (in shares)			1,655	25	11,822	25
Amount available for future sale of shares pursuant to the sales agreement			$ 3,700,000		$ 3,700,000		$ 3,700,000	$ 1,000,000
Maximum | AGP 2023 Sales Agreement
Class of Stock [Line Items]
Aggregate authorized offering price	$ 5,800,000
Proceeds from issuance of common stock				$ 1,000		$ 1,000

STOCKHOLDERS' EQUITY (Registere

STOCKHOLDERS' EQUITY (Registered Direct Offering) (Details)			1 Months Ended	6 Months Ended
	Jun. 08, 2023 USD ($) $ / shares Y shares	Jun. 07, 2023 USD ($)	Jun. 30, 2023 $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares	Dec. 31, 2023 $ / shares
Class of Stock [Line Items]
Common stock, par value (in $ per share) | $ / shares				$ 0.01		$ 0.01
Proceeds from issuance of common stock | $				$ 78,000	$ 2,245,000
Amount available for future sale of shares pursuant to the sales agreement | $				1,000,000
Registered Direct Offering
Class of Stock [Line Items]
Stock reserved for future issuance | shares	206,250
Common stock, par value (in $ per share) | $ / shares	$ 0.01
Share price (in dollars per share) | $ / shares	$ 9
Gross proceeds | $	$ 2,000,000
Threshold beneficial ownership percentage of warrants with its affiliates	4.99%
Threshold beneficial ownership percentage of warrants at the election of the purchaser	9.99%
Threshold ownership percentage of warrants	19.99%
Notice period to alter beneficial ownership percentage	61 days
Proceeds from issuance of common stock | $	$ 1,800,000
Lock-in period	90 days
Resale registration period	30 days
Cash fee paid | $		$ 140,000
Sale lock in period	90 days
Variable rate transaction lock in period	180 days
Amount available for future sale of shares pursuant to the sales agreement | $				$ 3,700,000
Pre-Funded Warrants | Registered Direct Offering
Class of Stock [Line Items]
Share price (in dollars per share) | $ / shares	$ 8.98
Class of warrant, number of securities called by warrants | shares	15,972			0
Exercise price (in dollars per share) | $ / shares	$ 0.02
RDO Common Warrants
Class of Stock [Line Items]
Class of warrant, number of securities called by warrants | shares			444,444	444,444	444,444
Exercise price (in dollars per share) | $ / shares			$ 12.60	$ 12.60	$ 12.60
Period from issuance after which the warrants become exercisable			6 months
RDO Common Warrants | Registered Direct Offering
Class of Stock [Line Items]
Class of warrant, number of securities called by warrants | shares	444,444
Exercise price (in dollars per share) | $ / shares	$ 12.60
Period from issuance after which the warrants become exercisable	6 months
Fair value of warrants issued | $	$ 3,500,000
Gross proceeds | $	$ 1,300,000
Term | RDO Common Warrants | Registered Direct Offering
Class of Stock [Line Items]
Fair value of warrant input | Y	5
Risk free rate | RDO Common Warrants | Registered Direct Offering
Class of Stock [Line Items]
Fair value of warrant input	0.0389
Volatility | RDO Common Warrants | Registered Direct Offering
Class of Stock [Line Items]
Fair value of warrant input	1.43
Share price | RDO Common Warrants | Registered Direct Offering
Class of Stock [Line Items]
Fair value of warrant input | $ / shares	9

STOCKHOLDERS' EQUITY (Preferred

STOCKHOLDERS' EQUITY (Preferred Stock) (Details) - shares	Jun. 30, 2024	Dec. 31, 2023
STOCKHOLDERS' EQUITY [Abstract]
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000

STOCKHOLDERS' EQUITY (Series B

STOCKHOLDERS' EQUITY (Series B Preferred Stock) (Details) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Aug. 28, 2017
Class of Stock [Line Items]
Preferred stock, shares authorized (in shares)	15,000,000		15,000,000		15,000,000
Preferred stock, shares issued (in shares)	47		47		47
Preferred stock, shares outstanding (in shares)	47		47		47
Preferred stock, par value (in dollars per share)	$ 0.01		$ 0.01		$ 0.01
Preferred Class B
Class of Stock [Line Items]
Number of shares converted (in shares)	0	0	0	0
Preferred stock, shares authorized (in shares)	6,900		6,900		6,900	6,900
Preferred stock, shares issued (in shares)	6,900		6,900		6,900
Preferred stock, shares outstanding (in shares)	47		47		47
Preferred stock, liquidation preference (in dollars per share)	$ 1,000		$ 1,000			$ 1,000
Preferred stock, par value (in dollars per share)						$ 0.01
Preferred stock, dividend rate (percentage)			0%
Conversion price (in dollars per share)	$ 8		$ 8
Number of common shares issuable upon conversion of preferred stock	5,875		5,875

STOCKHOLDERS' EQUITY (Schedule

STOCKHOLDERS' EQUITY (Schedule of Warrants) (Details) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Class of Stock [Line Items]
Warrants expired	15,091	7,419	15,091	7,419
RDO Common Warrants
Class of Stock [Line Items]
Underlying shares (in shares)	444,444	444,444	444,444	444,444
Exercise price (in dollars per share)	$ 12.60	$ 12.60	$ 12.60	$ 12.60

STOCKHOLDERS' EQUITY (Warrants)

STOCKHOLDERS' EQUITY (Warrants) (Details) - RDO Common Warrants - $ / shares	1 Months Ended
	Jun. 30, 2023	Jun. 30, 2024
Class of Warrant or Right [Line Items]
Number of warrants issued	444,444
Class of warrant, number of securities called by warrants	444,444	444,444
Period from issuance after which the warrants become exercisable	6 months
Exercise price (in dollars per share)	$ 12.60	$ 12.60

FAIR VALUE (Narratives) (Detail

FAIR VALUE (Narratives) (Details) - Warrant Liabilities [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2023 Y
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and rights outstanding	$ 0		$ 0
Revaluation recognized in earnings	$ 0		$ 0
Minimum [Member] | Measurement Input, Price Volatility [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input					0.71
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input					0.0533
Minimum [Member] | Measurement Input, Expected Term [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input | Y					0.3
Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Revaluation recognized in earnings		$ 1,000		$ 1,000
Maximum [Member] | Measurement Input, Price Volatility [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input					0.77
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input					0.0540
Maximum [Member] | Measurement Input, Expected Term [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input | Y					0.4

EQUITY INCENTIVE PLAN (Narrativ

EQUITY INCENTIVE PLAN (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 300	$ 400	$ 700	$ 800
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)			75,862
Granted (in dollars per share)			$ 4.99
Weighted average grant date fair value (in dollars per share)			$ 4.54
Risk free interest rate, minimum			3.94%
Risk free interest rate, maximum			4.26%
Term			6 years
Stock options, expected to vest, outstanding (in shares)	262,591		262,591
Stock options, expected to vest, outstanding, aggregate intrinsic value	$ 5		$ 5
Stock options, expected to vest remaining contractual term			7 years 7 months 6 days
Unrecognized compensation expense related to unvested stock awards	$ 1,800		$ 1,800
Unvested stock options, unrecognized compensation expense weighted average recognition period (in years)			1 year 10 months 24 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, expected to vest, outstanding (in shares)	2,492		2,492
Restricted stock granted	0	0	0	0
Awards outstanding (in shares)	0		0
Minimum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility rate			133%
Maximum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, unvested options, vesting period			4 years
Volatility rate			139%
Equity Incentive Plan 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	320,699		320,699
Shares available for grant	14,113		14,113
Percentage of annual increase in number of shares authorized for grant			5%
Number of additional shares authorized			71,006
Equity Incentive Plan 2017 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Plan expiration date			Jun. 05, 2027

EQUITY INCENTIVE PLAN (Summary

EQUITY INCENTIVE PLAN (Summary of Stock Option Activity) (Details) - Employee Stock Option [Member]	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Number of Options
Outstanding at beginning of period (in shares) | shares	232,744
Granted (in shares) | shares	75,862
Forfeited (in shares) | shares	(4,581)
Outstanding at end of period (in shares) | shares	304,025
Exercisable at end of period (in shares) | shares	176,276
Weighted-Average Exercise Price
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 46.56
Granted (in dollars per share) | $ / shares	4.99
Forfeited (in dollars per share) | $ / shares	19.76
Outstanding at end of period (in dollars per share) | $ / shares	36.59
Exercisable at end of period (in dollars per share) | $ / shares	$ 52.18

SALES SERVICE REVENUE, NET AN_3

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Narrative) (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($) segment	Jun. 30, 2023 segment	Jun. 30, 2024 USD ($) segment	Jun. 30, 2023 segment	Dec. 31, 2023 USD ($)
SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE [Abstract]
Number of segments | segment	1	1	1	1
Deferred revenue | $	$ 260		$ 260		$ 110

SALES SERVICE REVENUE, NET AN_4

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Net Revenues) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	$ 4,507	$ 3,645	$ 7,985	$ 6,474
Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	3,909	2,768	6,730	4,836
Medicaid | Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	20	5	25	13
Medicaid | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	20	5	25	13
Medicare | Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	1,525	1,165	2,616	2,045
Medicare | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	1,525	1,165	2,616	2,045
Self-Pay | Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	14	36	32	116
Self-Pay | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	14	36	32	116
Third party payers | Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	2,348	1,562	4,053	2,662
Third party payers | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	2,348	1,562	4,053	2,662
Contract diagnostics and other | Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	2		4
Contract diagnostics and other | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	2		4
Service revenue, net | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	$ 3,909	$ 2,768	$ 6,730	$ 4,836

SALES SERVICE REVENUE, NET AN_5

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Gross to Net Sales Adjustments) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disaggregation of Revenue [Line Items]
Gross revenue	$ 10,120	$ 7,525	$ 17,861	$ 13,089
Contractual allowance and adjustments	(5,613)	(3,880)	(9,876)	(6,615)
Service revenue, net	4,507	3,645	7,985	6,474
Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	9,522	6,648	16,606	11,451
Contractual allowance and adjustments	(5,613)	(3,880)	(9,876)	(6,615)
Service revenue, net	3,909	2,768	6,730	4,836
Service revenue, net [Member] | Medicaid [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	20	5	25	13
Service revenue, net	20	5	25	13
Service revenue, net [Member] | Medicare [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	1,525	1,165	2,616	2,045
Service revenue, net	1,525	1,165	2,616	2,045
Service revenue, net [Member] | Self-Pay
Disaggregation of Revenue [Line Items]
Gross revenue	14	36	32	116
Service revenue, net	14	36	32	116
Service revenue, net [Member] | Third-Party Payers [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	7,961	5,442	13,929	9,277
Contractual allowance and adjustments	(5,613)	(3,880)	(9,876)	(6,615)
Service revenue, net	2,348	1,562	4,053	2,662
Service revenue, net [Member] | Contract Diagnostic Services [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	2		4
Service revenue, net	2		4
Product [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	598	877	1,255	1,638
Service revenue, net	$ 598	$ 877	$ 1,255	$ 1,638

SALES SERVICE REVENUE, NET AN_6

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Sales, Net of Collection Allowance) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	$ 4,507	$ 3,645	$ 7,985	$ 6,474
Allowance for credit losses	(66)	(112)	(112)	(124)
Net sales	4,441	3,533	7,873	6,350
Medicaid [Member]
Disaggregation of Revenue [Line Items]
Allowance for credit losses			(9)
Medicare [Member]
Disaggregation of Revenue [Line Items]
Allowance for credit losses			(39)
Third-Party Payers [Member]
Disaggregation of Revenue [Line Items]
Allowance for credit losses			(61)
Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	3,909	2,768	6,730	4,836
Allowance for credit losses	(66)	(112)	(112)	(124)
Net sales	3,843	2,656	6,618	4,712
Service revenue, net [Member] | Medicaid [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	20	5	25	13
Allowance for credit losses	(7)	(2)	(9)	(6)
Net sales	13	3	16	7
Service revenue, net [Member] | Medicare [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	1,525	1,165	2,616	2,045
Allowance for credit losses	(23)	(23)	(39)	(23)
Net sales	1,502	1,142	2,577	2,022
Service revenue, net [Member] | Self-Pay
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	14	36	32	116
Allowance for credit losses	(1)	(4)	(3)	(12)
Net sales	13	32	29	104
Service revenue, net [Member] | Third-Party Payers [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	2,348	1,562	4,053	2,662
Allowance for credit losses	(35)	(83)	(61)	(83)
Net sales	2,313	1,479	3,992	2,579
Service revenue, net [Member] | Contract Diagnostic Services [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	2		4
Net sales	2		4
Product [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	598	877	1,255	1,638
Net sales	$ 598	$ 877	$ 1,255	$ 1,638

SALES SERVICE REVENUE, NET AN_7

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Receivables) (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Accounts receivable, gross	$ 3,791	$ 3,873
Less allowance for doubtful accounts	(2,684)	(2,572)
Accounts receivable, net	1,107	1,301
Medicaid [Member]
Disaggregation of Revenue [Line Items]
Accounts receivable, gross	20	25
Medicare [Member]
Disaggregation of Revenue [Line Items]
Accounts receivable, gross	2,034	1,561
Self-Pay
Disaggregation of Revenue [Line Items]
Accounts receivable, gross	196	229
Third-Party Payers [Member]
Disaggregation of Revenue [Line Items]
Accounts receivable, gross	1,293	1,641
Contract Diagnostic Services and Other [Member]
Disaggregation of Revenue [Line Items]
Accounts receivable, gross	$ 248	$ 417

SALES SERVICE REVENUE, NET AN_8

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Allowance for Doubtful Accounts) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Allowance for doubtful accounts, Beginning balance			$ (2,572)
Adjustment for allowance for credit losses	$ (66)	$ (112)	(112)	$ (124)
Total charges			(112)
Allowance for doubtful accounts, Ending balance	$ (2,684)		(2,684)
Medicaid [Member]
Adjustment for allowance for credit losses			(9)
Medicare [Member]
Adjustment for allowance for credit losses			(39)
Self-Pay [Member]
Adjustment for allowance for credit losses			(3)
Third-Party Payers [Member]
Adjustment for allowance for credit losses			$ (61)

SALES SERVICE REVENUE, NET AN_9

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Customer Revenue and Accounts Receivable Concentrations) (Details) - Customer Concentration Risk [Member]	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Sales Revenue, Net [Member] | Customer A
Concentration Risk [Line Items]
Concentration risk, percentage		11%		14%
Sales Revenue, Net [Member] | Customer C
Concentration Risk [Line Items]
Concentration risk, percentage	12%
Accounts Receivable [Member] | Customer A
Concentration Risk [Line Items]
Concentration risk, percentage			12%
Accounts Receivable [Member] | Customer B
Concentration Risk [Line Items]
Concentration risk, percentage					13%
Accounts Receivable [Member] | Customer C
Concentration Risk [Line Items]
Concentration risk, percentage			21%